Ginsenoside Rh2 (G‑Rh2) is a natural bioactive product derived from Meyer (). G‑Rh2 exhibits anticancer activity in various human cancer cell lines both and by modulating several signaling pathways, such as those of PDZ‑binding kinase/T‑LAK cell‑originated protein kinase, phosphatidylinositol 3‑kinase, protein kinase B, mammalian target of rapamycin, epidermal growth factor receptor, p53, and reactive oxygen species. Moreover, G‑Rh2 could effectively reverse drug resistance and enhance therapeutic effects in cancer therapy. This review summarizes the chemical properties, and anticancer activity, and underlying molecular mechanisms of G‑Rh2 to facilitate cancer chemoprevention studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/or.2021.7984 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibition of macrophage polarization and pyroptosis in collagen-induced arthritis through MSC-exo and ginsenoside Rh2.
Arthritis Res Ther
January 2025
Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation, tissue damage, and fibrosis, significantly affecting the quality of life. While there are currently some effective treatments available, they often come with side effects. There is an urgent need to find new treatments that can further improve therapeutic outcomes and reduce side effects.
View Article and Find Full Text PDFGinsenoside Rh2 promotes cell apoptosis in T-cell acute lymphocytic leukaemia by MAPK and PI3K/AKT signalling pathways.
Nat Prod Res
December 2024
State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Fermentation Microbiology, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China.
T-cell acute lymphoblastic leukaemia (T-ALL) is a common childhood malignant tumour, which has poor prognosis and high recurrence rate. Ginsenoside Rh2 (GRh2), a bioactive ingredient of has significant anti-tumour effect. In this study, we found that gene expressions of Jurkat cells were significantly changed in the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) signalling pathways after 35 µm GRh2 treatment, involving in JUN, PIEN, AKT3 and MAPK8IP2.
View Article and Find Full Text PDFMechanism of action of protopanaxadiol ginsenosides on hepatocellular carcinoma and network pharmacological analysis.
Chin Herb Med
October 2024
College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Article Synopsis
- * Ginsenosides like Rb, Rd, Rg, and Rh show anti-inflammatory and anti-tumor effects, and research indicates PDs can inhibit HCC development by targeting multiple signaling pathways.
- * This review explores the anti-HCC effects of PDs, their mechanisms, and highlights the necessity for further studies to optimize PDs for safe and effective clinical use.
20(S)-Ginsenoside Rh2 induces apoptosis and autophagy in melanoma cells via suppressing Src/STAT3 signaling.
J Ginseng Res
November 2024
Department of Biology, Hong Kong Baptist University (HKBU), Kowloon Tong, Kowloon, Hong Kong, China.
Background: 20(S)-Ginsenoside Rh2 (GRh2) has been extensively studied for multifaceted health benefits. However, the anti-melanoma effect of GRh2 remains poorly understood. Herein, the anti-melanoma effects and underlying mechanisms of GRh2 were investigated.
View Article and Find Full Text PDFMesoporous Silica Nano-Modified Ginsenoside Rh2 Promote Tumor Immunosuppression and Inhibit Lung Cancer Development through the PD-1/PD-L1 Pathway.
Ann Clin Lab Sci
September 2024
Department of Thoracic Surgery, First People's Hospital of Shuangliu District, Chengdu, Sichuan, China.
Objective: To explore the mechanism for mesoporous silica nano-modified ginsenoside Rh2 promoting tumor immunosuppression in lung cancer through PD-1/PD-L1 pathway.
Methods: Firstly, G-Rh2-MSN were prepared and lung cancer A549 cells were cultured. The following groups were set up to analyze whether G-Rh2-MSN down-regulates PD-1/PD-L1 to promote tumor immunity, inhibit activities of lung cancer cells, and promote apoptosis: Model control group, G-Rh2 group, G-Rh2-MSN group, G-Rh2-MSN+PT001 group, G-Rh2-MSN+nivolumab group, G-Rh2-MSN+Durvalumab group, G-Rh2-MSN+atezolizumab group, and G-Rh2-MSN+nivolumab+Durvalumab group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!